Telix Pharmaceuticals Begins Phase 3 Trial for Brain Cancer Therapy
Telix Pharmaceuticals (TLX) has initiated the first patient dosing in its Phase 3 IPAX-BrIGHT trial for a radiopharmaceutical therapy targeting recurrent glioblastoma. The trial evaluates TLX101-Tx in combination with lomustine, aiming to deliver targeted radiation to tumor sites. This marks a significant milestone in the development of a potential first-in-class therapy for a disease with limited treatment options.
Topics: brain cancer clinical trials glioblastoma Phase 3 radiopharmaceutical therapy